내부자 거래

EDGAR

Evoke Pharma Inc

이사, 임원 및 10% 이상 주주가 SEC 양식 3, 4, 5로 보고한 거래이며, 각 제출 문서의 XML에서 읽었습니다. 코드와 그 설명은 SEC의 원문입니다.

양식 4는 거래 후 영업일 2일 이내에 제출해야 하므로 가장 최근 거래는 아직 제출되지 않았을 수 있습니다.

기간: 2025년 11월 16일 이후 날짜의 거래.

공개시장 매수(코드 P)
거래 0건, —주
공개시장 매도(코드 S)
거래 0건, —주

합계는 나열된 제출 거래를 더한 것이며, 보고된 내용을 센 것일 뿐 방향을 나타내지 않습니다.

37건 중 1–37건 표시

SEC 양식 3, 4, 5에 제출된 내부자 거래(최신순)
날짜보고자코드취득 또는 처분주식 수주당 가격(제출된 대로)가치(산출)거래 후 보유 주식 수직접 또는 간접규칙 10b5-1 체크란주석출처
2025년 12월 17일 2025년 12월 19일 제출Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
처분(D)148,15311.00
1,629,683

산출: 주식 수 × 주당 가격. 정확한 값 1629683.00.

0간접(I) See Footnote아니요
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 19일 제출Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

파생증권: Prefunded Warrants — 기초자산 Common Stock (433,962) — 행사가 0.0001
처분(D)433,96210.999
4,773,148.038

산출: 주식 수 × 주당 가격. 정확한 값 4773148.038.

0간접(I) See Footnote아니요
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 19일 제출Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

파생증권: Series A Common Stock Purchase Warrants — 기초자산 Common Stock (117,019) — 행사가 8.16
처분(D)117,0194.71
551,159.49

산출: 주식 수 × 주당 가격. 정확한 값 551159.49.

0간접(I) See Footnote아니요
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 19일 제출Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

파생증권: Series C Common Stock Purchase Warrants — 기초자산 Common Stock (117,019) — 행사가 8.16
처분(D)117,0194.71
551,159.49

산출: 주식 수 × 주당 가격. 정확한 값 551159.49.

0간접(I) See Footnote아니요
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 19일 제출Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

파생증권: Amended Series A Common Stock Purchase Warrants — 기초자산 Common Stock (158,531) — 행사가 0.01
처분(D)158,53110.99
1,742,255.69

산출: 주식 수 × 주당 가격. 정확한 값 1742255.69.

0간접(I) See Footnote아니요
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 19일 제출Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

파생증권: Amended Series C Common Stock Purchase Warrants — 기초자산 Common Stock (250,627) — 행사가 0.01
처분(D)250,62710.99
2,754,390.73

산출: 주식 수 × 주당 가격. 정확한 값 2754390.73.

0간접(I) See Footnote아니요
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,218) — 행사가 5.41
처분(D)1,218——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322642 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 4.45
처분(D)5,833——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322642 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,218) — 행사가 3.453
처분(D)1,218——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322642 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,479) — 행사가 5.41
처분(D)1,479——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322643 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (8,750) — 행사가 4.45
처분(D)8,750——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322643 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,291) — 행사가 3.453
처분(D)1,291——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322643 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,187) — 행사가 5.41
처분(D)1,187——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322641 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 4.45
처분(D)5,833——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322641 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,187) — 행사가 3.453
처분(D)1,187——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322641 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,250) — 행사가 5.41
처분(D)1,250——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322638 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 4.45
처분(D)5,833——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322638 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,250) — 행사가 3.453
처분(D)1,250——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322638 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,218) — 행사가 5.41
처분(D)1,218——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322639 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 4.45
처분(D)5,833——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322639 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,187) — 행사가 3.453
처분(D)1,187——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322639 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 5.51
처분(D)5,833——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322645 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,125) — 행사가 3.453
처분(D)1,125——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322645 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (17,291) — 행사가 5.27
처분(D)17,291——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322644 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (11,000) — 행사가 4.45
처분(D)11,000——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322644 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (64,840) — 행사가 5.27
처분(D)64,840——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322637 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (70,000) — 행사가 4.45
처분(D)70,000——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322637 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (17,291) — 행사가 5.27
처분(D)17,291——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322640 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (13,000) — 행사가 4.45
처분(D)13,000——0직접(D) 아니요
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322640 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 5.26
처분(D)5,833——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322646 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 17일 2025년 12월 17일 제출PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,155) — 행사가 3.453
처분(D)1,155——0직접(D) 아니요
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
제출 문서 열기 0001193125-25-322646 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 16일 2025년 12월 17일 제출Hill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
처분(D)133——0직접(D) 아니요
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
제출 문서 열기 0001193125-25-322642 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 16일 2025년 12월 17일 제출GARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
처분(D)2,330——0간접(I) By Garner Investments, L.L.C.아니요
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
제출 문서 열기 0001193125-25-322643 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 16일 2025년 12월 17일 제출Brady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
처분(D)27——0직접(D) 아니요
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
제출 문서 열기 0001193125-25-322639 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 16일 2025년 12월 17일 제출CARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
처분(D)360——0직접(D) 아니요
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
제출 문서 열기 0001193125-25-322644 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 16일 2025년 12월 17일 제출D'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
처분(D)15,509——0직접(D) 아니요
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
제출 문서 열기 0001193125-25-322637 제출 문서의 XML에서 읽음 이 행에 이의 제기
2025년 12월 16일 2025년 12월 17일 제출Kowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
처분(D)11,815——0직접(D) 아니요
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
제출 문서 열기 0001193125-25-322640 제출 문서의 XML에서 읽음 이 행에 이의 제기

기관 보유자(양식 13F)

저장소에 이 발행사로 연결된 양식 13F 보유 내역이 없습니다. 아직 연결되지 않았거나 제출하지 않은 보유자는 0이 아니라 없는 것입니다.

5% 보유자(스케줄 13D, 13G)

SEC 구조화 형식(2024년 말 이후)으로 제출된 스케줄을 여기서 읽습니다. 이전 스케줄은 자유 텍스트여서 읽지 않습니다.

5% 보유자, 최신 사건순, 제출된 대로
보유자해당 종류 대비 비율보유 주식 수사건일양식출처
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00.0012/17/2025 2025년 12월 19일 제출SCHEDULE 13D/A정정 5제출 문서 열기 0001104659-25-123157 이 행에 이의 제기
Harkey Wilmot B. Common Stock, par value $0.0001 per share00.0012/17/2025 2025년 12월 19일 제출SCHEDULE 13D/A정정 5제출 문서 열기 0001104659-25-123157 이 행에 이의 제기
Mack Daniel Common Stock, par value $0.0001 per share00.0012/17/2025 2025년 12월 19일 제출SCHEDULE 13D/A정정 5제출 문서 열기 0001104659-25-123157 이 행에 이의 제기
Morgan Stanley Common Stock0.03111/30/2025 2025년 12월 5일 제출SCHEDULE 13G/A정정 1제출 문서 열기 0000895421-25-000595 이 행에 이의 제기
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 2025년 12월 5일 제출SCHEDULE 13G/A정정 1제출 문서 열기 0000895421-25-000595 이 행에 이의 제기
Klein Roger M. Common Stock, par value $0.0001 per share10.5163,000.0011/04/2025 2025년 11월 12일 제출SCHEDULE 13D제출 문서 열기 0001651175-25-000007 이 행에 이의 제기
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.3129,000.0011/04/2025 2025년 11월 12일 제출SCHEDULE 13D제출 문서 열기 0001651175-25-000007 이 행에 이의 제기
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 2025년 11월 4일 제출SCHEDULE 13D/A정정 4제출 문서 열기 0001104659-25-106048 이 행에 이의 제기
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 2025년 11월 4일 제출SCHEDULE 13D/A정정 4제출 문서 열기 0001104659-25-106048 이 행에 이의 제기
Mack Daniel Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 2025년 11월 4일 제출SCHEDULE 13D/A정정 4제출 문서 열기 0001104659-25-106048 이 행에 이의 제기
Morgan Stanley Common Stock10.5163,71808/31/2025 2025년 9월 8일 제출SCHEDULE 13G제출 문서 열기 0000895421-25-000528 이 행에 이의 제기
Morgan Stanley Smith Barney LLC Common Stock10.5163,71808/31/2025 2025년 9월 8일 제출SCHEDULE 13G제출 문서 열기 0000895421-25-000528 이 행에 이의 제기

비율은 제출 문서가 지정한 종류에 대한 것이며 보유자가 밝힌 그대로입니다. 그룹 구성원은 각자 그룹의 주식을 보고하므로 행을 합산하지 않습니다.

읽은 내용

2004년 6월 14일부터 2026년 11월 13일까지의 제출 문서 2,094,807건을 읽음: 양식 3, 3/A, 4, 4/A, 5, 5/A.

아카이브를 아직 읽는 중이라 일부 연도는 불완전할 수 있습니다. 여기서 제출 수가 적은 해가 실제로 적게 제출되었다는 뜻은 아닙니다.

제출 연도별 읽은 문서
제출 연도읽은 문서
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024187,785
2025235,520
2026254,737

SEC가 XML을 요구하기 전의 제출 문서는 목록에만 있고 내용은 추출하지 않습니다.

Evoke Pharma Inc(으)로 돌아가기